Alex Courville, MD
Family Medicine · Kinder, LANPI 1578983367
Payments from drug & device makers
Across 235 payments — averaging $17.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$462
- Supernus Pharmaceuticals, Inc.$295
- Amgen$241
- Astellas Pharma US Inc$215
- Axsome Therapeutics, Inc.$200
- plus $1K from 27 others
What the payments were for
- Food & beverage$4,07899%
- Education$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 89 | $1,199 |
| AstraZeneca | 23 | $462 |
| Supernus Pharmaceuticals, Inc. | 6 | $295 |
| Amgen | 7 | $241 |
| Astellas Pharma US Inc | 12 | $215 |
| Axsome Therapeutics, Inc. | 11 | $200 |
| Lilly USA, LLC | 9 | $183 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $178 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $144 |
| Pfizer | 8 | $126 |
| Novo Nordisk | 7 | $112 |
| Sumitomo Pharma America, Inc. | 4 | $95 |
| Bayer | 5 | $71 |
| Vanda Pharmaceuticals Inc. | 2 | $56 |
| GSK | 2 | $46 |
| Novartis | 3 | $45 |
| Ironshore Pharmaceuticals Inc. | 3 | $45 |
| Abbott | 2 | $44 |
| Exact Sciences | 2 | $35 |
| Evofem Biosciences, Inc. | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
| Indivior Inc. | 2 | $32 |
| Gilead | 2 | $32 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Boehringer Ingelheim | 2 | $28 |
| Dexcom, Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $19 |
| Braeburn Inc. | 1 | $17 |
| Boston Scientific | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $12 |
| Eisai Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,108 in reported general payments places this provider in the 75th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 134 | $149,311 |
| MounjaroTirzepatide | 108 | $131,551 |
| EliquisApixaban | 118 | $106,394 |
| OzempicSemaglutide | 90 | $82,626 |
| JardianceEmpagliflozin | 87 | $61,404 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 21 | $41,290 |
| XareltoRivaroxaban | 88 | $40,318 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $32,650 |
| FarxigaDapagliflozin Propanediol | 42 | $31,380 |
| LinzessLinaclotide | 42 | $26,007 |
| Breo ElliptaFluticasone/Vilanterol | 52 | $19,552 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $18,012 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 19 | $10,985 |
| RybelsusSemaglutide | 12 | $10,963 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 52 | $10,395 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $183 | $280,862242 claims |
| PfizerEliquis | $126 | $106,394118 claims |
| Novo NordiskOzempic, Rybelsus | $112 | $93,588102 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $28 | $66,85998 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $46 | $61,959123 claims |
| GileadBiktarvy | $32 | $41,29021 claims |
| AstraZenecaFarxiga | $462 | $31,38042 claims |
| AbbVieLinzess | $1,199 | $26,00742 claims |
| Astellas Pharma US IncMyrbetriq | $215 | $8,49115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Kinder
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Ramon VargasKenner$2.1M
- Stephen JonesNew Orleans$513K
- Joshua WhatleyLake Charles$366K
- Richard JeansonneMandeville$362K
- Kristen ThomasNew Orleans$361K
- Clint WilsonBossier City$208K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.